Please login to the form below

Not currently logged in
Email:
Password:

R&D news in brief

Our weekly round up of R&D news in brief

New ADHD drug edges closer to launch

US company Cephalon says it has received an approvable letter from the US Food and Drug Administration for a new drug to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents. The drug, which would be sold in the US under the brand name Sparlon, would be co-marketed with a unit of Johnson & Johnson. Dr Chris Kratochvil, an associate psychiatry professor at the University of Nebraska Medical Centre said that although other ADHD drugs such as Novartis' Ritalin and Shire's Adderall were effective overall, doctors needed additional options because not all drugs were effective in individual patients.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics